- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
China has approved a monoclonal neutralizing antibody (mAb) therapy, the first locally-discovered and approved SARS-CoV-2 target-specific treatment. It is an antibody cocktail of mubarvimab/romlusevimab meant for treating adults and pediatric patients (age 12-17 weighing at least 40 kg) with mild and normal type of COVID-19 at high risk for progression to severe disease. Phase lll clinical trial showed promising results with about 78% decline in hospitalisation and death among COVID-19 patients who were not hospitalised and had a higher risk of developing severe disease. This therapy is manufactured by Brii Biosciences.
Additional data provided by
English
Japanese
